Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs …
Oct 10, 2024 · First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) Results to be shared with global health authorities to potentially update the TALZENNA label Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall ...
Pfizer's cancer drug combo improves overall survival in late-stage ...
6 days ago · Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a late-stage study.
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs …
6 days ago · "The TALAPRO-2 results showed that TALZENNA plus XTANDI is the first and only PARP inhibitor in combination with an ARPI to significantly improve survival in patients with metastatic castration ...
Pfizer’s TALZENNA ® in Combination with XTANDI - Business Wire
Oct 10, 2024 · TALZENNA ® (talazoparib ... In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com ...
Pfizer’s TALZENNA® in Combination with XTANDI ... - Morningstar
Oct 10, 2024 · TALZENNA ® (talazoparib ... In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com ...
Pfizer Phase III Prostate Cancer Win Builds Case for Broader
6 days ago · Pfizer on Thursday announced that a combination regimen of its PARP inhibitor Talzenna and ARPI drug Xtandi improved survival in patients with metastatic castration-resistant prostate cancer, according to a topline analysis of the Phase III TALAPRO-2 study.. Specific data in the announcement were sparse, with Pfizer revealing only that Talzenna plus Xtandi led to a “statistically significant ...
Pfizer’s TALZENNA® in Combination with XTANDI® Receives …
Nov 13, 2023 · TALZENNA (talazoparib) is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death.
Pfizer Announces Positive TALZENNA® and XTANDI® …
Feb 16, 2023 · TALZENNA (talazoparib) is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.
Pfizer reports positive data from prostate cancer combination …
5 days ago · Pfizer has announced positive topline data from the Phase III TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI (enzalutamide) in patients with mCRPC. TALZENNA is an oral poly ADP-ribose ...
European Commission Approves Pfizer’s TALZENNA - Business Wire
Jan 8, 2024 · TALZENNA (talazoparib) is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme...